Relapses Requiring Intravenous Steroid Use and Multiple Sclerosis (MS)-Related Hospitalizations: An Integrated Analysis of the BG-12 (Dimethyl Fumarate) Phase 3 Studies (P07.121)
Gavin Giovannoni,Ralf Gold,Robert J. Fox,Ludwig Kappos,Mariko Kita,Minhua Yang+5 more-2013-02-12-Neurology
1
TL;DRAbstract
OBJECTIVE: To report the effects of BG-12 (dimethyl fumarate) on number of relapses requiring intravenous (IV) steroids and MS-related hospitalizations, from a pre-specified integrated analysis of DEFINE and CONFIRM designed to estimate more precisely the therapeutic effect of dimethyl fumarate versus placebo.
Chat with Paper
AI Agents for this Paper
OBJECTIVE: To report the effects of BG-12 (dimethyl fumarate) on number of relapses requiring intravenous (IV) steroids and MS-related hospitalizations, from a pre-specified integrated analysis of DEFINE and CONFIRM designed to estimate more precisely the therapeutic effect of dimethyl fumarate versus placebo.
Keywords
Dimethyl fumaratePlaceboMedicineClinical endpointMultiple sclerosisConfidence intervalInternal medicinePhases of clinical research
Chat
Click to start Chat